当前位置: X-MOL 学术Eur. Neuropsychopharm. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Neurological soft signs in schizophrenia spectrum disorders are not confounded by current antipsychotic dosage
European Neuropsychopharmacology ( IF 5.6 ) Pub Date : 2020-02-01 , DOI: 10.1016/j.euroneuro.2019.11.001
Stefan Fritze 1 , Fabio Sambataro 2 , Katharina M Kubera 3 , Alina L Bertolino 1 , Cristina E Topor 1 , Robert C Wolf 3 , Dusan Hirjak 1
Affiliation  

Neurological soft signs (NSS) have garnered increasing attention in psychiatric research on motor abnormalities in schizophrenia spectrum disorders (SSD). However, it remains unclear whether the assessment of NSS severity could have been confounded by current antipsychotic dosage. In this study, we recruited 105 patients with SSD that underwent a comprehensive motor assessment evaluating NSS and extrapyramidal motor symptoms (EPMS) by means of standardized instruments. Current antipsychotic dosage equivalence estimates were determined by the classical mean dose method (doses equivalent to 1 mg/d olanzapine). We used multiple regression analyses to describe the relationship between NSS, EPMS and antipsychotic medication. In line with our expectations, current antipsychotic dosage had no significant effects on NSS total score (p = 0.27), abnormal involuntary movements (p = 0.17), akathisia (p = 0.32) and parkinsonism (p = 0.26). Further, NSS total score had a significant effect on akathisia (p = 0.003) and parkinsonism (p = 0.0001, Bonferroni corr.), but only marginal effect on abnormal involuntary movements (p = 0.08). Our results support the notion that NSS are not significantly modulated by current antipsychotic dosage in SSD. The associations between NSS, akathisia and parkinsonism, as revealed by this study, support the genuine rather than medication-dependent origin of particular motor abnormalities in SSD.

中文翻译:

当前抗精神病药物剂量不会混淆精神分裂症谱系障碍的神经软体征

神经软体征 (NSS) 在精神分裂症谱系障碍 (SSD) 运动异常的精神病学研究中越来越受到关注。然而,目前尚不清楚 NSS 严重程度的评估是否会被当前的抗精神病药剂量混淆。在这项研究中,我们招募了 105 名 SSD 患者,他们通过标准化仪器进行了综合运动评估,评估了 NSS 和锥体外系运动症状 (EPMS)。当前的抗精神病药剂量等效估计值由经典平均剂量法确定(剂量相当于 1 mg/d 奥氮平)。我们使用多元回归分析来描述 NSS、EPMS 和抗精神病药物之间的关系。与我们的预期一致,目前的抗精神病药剂量对 NSS 总分没有显着影响(p = 0.27),异常不自主运动 (p = 0.17)、静坐不能 (p = 0.32) 和帕金森综合征 (p = 0.26)。此外,NSS 总分对静坐不能 (p = 0.003) 和帕金森症 (p = 0.0001,Bonferroni corr.) 有显着影响,但对异常不自主运动 (p = 0.08) 仅有边际影响。我们的结果支持 NSS 不受当前 SSD 中抗精神病药物剂量显着调节的观点。正如本研究所揭示的,NSS、静坐不能和帕金森症之间的关联支持 SSD 中特定运动异常的真实而非药物依赖性起源。08)。我们的结果支持 NSS 不受当前 SSD 中抗精神病药物剂量显着调节的观点。正如本研究所揭示的,NSS、静坐不能和帕金森症之间的关联支持 SSD 中特定运动异常的真实而非药物依赖性起源。08)。我们的结果支持 NSS 不受当前 SSD 中抗精神病药物剂量显着调节的观点。正如本研究所揭示的,NSS、静坐不能和帕金森症之间的关联支持 SSD 中特定运动异常的真实而非药物依赖性起源。
更新日期:2020-02-01
down
wechat
bug